Marksans Pharma Limited Company Profile
|
|
Marksans Pharma (MARKSANS), incorporated in 2001 as a wholly owned subsidiary of Glenmark Pharmaceuticals, is a fully integrated pharmaceutical company into both pharmaceuticals and biopharmaceuticals. It was spun off into a separate entity called Glenmark Laboratories in March 2003 and subsequently changed its name to the present one in 2005.
Focusing on its specialty prescription drugs, the company manufactures drugs spanning oncology, antidiabetic, cardiovascular, pain management, gynaecology, gastroenterology, and other medical fields. It has also made inroads into complex and intricate markets dealing with biotechnology and neuro-psychiatry. World-class state-of-the-art manufacturing facilities have been established, incorporating best practices, adhering to stringent regulatory compliances, built as per US FDA guidelines, and approved by venerated UK MHRA, Australia TGA and Brazilian ANVISA health authorities.
Two API plants situated near Kurkumbh in Pune produce various bulk drugs and intermediates with a combined production capacity of 1,140 TPA. The formulation plant in Goa is one of the biggest manufacturing facilities for soft gelatin in Asia with a capacity of 2.5 billion tablets/line/annum and 1.2 billion capsules/line/annum. A plant at Southport in the UK manufactures non-sterile liquids, ointments and powder products and has a laboratory to develop and improve formulations. It has embarked on ambitious expansion projects to scale up its existing capacity for entry into new therapeutic segments covering high growth lifestyle-related diseases and to be present over the entire value chain of the drug discovery and development process. Two R&D laboratories, one each in Goa and Delhi, focus on innovation in the area of new molecule and drug delivery systems.
R&D facilities have been enhanced in Australia through its subsidiary, Nova Pharmaceuticals Australasia PTY, an Australian company acquired in 2005. This subsidiary currently has a basket of 14 products with an additional 25 products filed for TGA approvals, and specializes in marketing generic pharma products. The company has acquired the Hale Group, UK, along with its subsidiary company Bell Sons & Co. in the year 2008. The group is a well-established manufacturer of a broad range of OTC pharmaceuticals having full approval of the UK MHRA and currently holds 38 product licences. The latest acquisition through a subsidiary, Marksans Pharma (UK), has been UK`s leading generic drug marketing and distribution company Relonchem.
Well established in the local as well as export markets, products are supplied to more than 54 countries. It is also expanding its business to other European markets through contract manufacturing and active product registrations. The company has now gained access to the Bell group`s 80-year expertise in the export markets and product reach in over 40 countries. It has built strong alliances and continuing relationships with top global generic companies and is increasing its footprints in the global pharmaceutical market by forging in-licensing arrangements with the world leaders of Pharma to launch their products in India and abroad.
The registered office is at 21st Floor Lotus Business Park, Off New Link Road, Andheri (W), Mumbai-400053. |
|
MARKSANS Intraday Realtime Chart
|
|
